Pediatric Cancer Studies: US FDA Eyes Waiver Framework For Same-In-Class Drugs

 
• By Sue Sutter
  
Framework
US FDA wants to build a transparent framework that it can consistently apply to decisionmaking about pediatric study waivers for cancer drugs. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers